A clinical update and global economic burden of Rheumatoid Arthritis

• Main Authors: Syed Ali Fazal, Mohammad Khan, Shamima E. Nishi, Fahmida Alam, Nowshin Zarin, Mohammad T. Bari, Ghulam Md. Ashraf
• Format: Indexed Article
• Published: Bentham Science Publishers 2018
• Online Access: http://discol.umk.edu.my/id/eprint/7407/; https://www.ncbi.nlm.nih.gov/pubmed/29141572

Rheumatoid arthritis (RA) is a predominant inflammatory autoimmune disorder. The incidence and prevalence of RA is increasing with considerable morbidity and mortality worldwide. The pathophysiology of RA has become clearer due to many significant research outputs during the last two decades. Many inflammatory cytokines involved in RA pathophysiology and the presence of autoantibodies are being used as potential biomarkers via the use of effective diagnostic techniques for the early diagnosis of RA. Currently, several disease-modifying anti-rheumatic drugs are being prescribed targeting RA pathophysiology, which have shown significant contributions in improving the disease outcomes.